FTSE MIB
34.018,22 +389,01 (+1,16%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,83 +0,72 (+0,92%) Bitcoin EUR
59.472,79 +383,03 (+0,65%)
Vigil Neuroscience, Inc. (VIGL)
Dopo ore:
| Chiusura precedente | 2,7400 |
| Aperto | 2,7200 |
| Denaro | 2,9400 x 100 |
| Lettera | 3,0300 x 100 |
| Min-Max giorno | 2,6700 - 3,0310 |
| Intervallo di 52 settimane | 2,5000 - 11,1100 |
| Volume | |
| Media Volume | 86.385 |
| Capitalizzazione | 113,88M |
| Beta (5 anni mensile) | 1,78 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,1300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,75 |
GlobeNewswireVigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 1:30
- GlobeNewswire
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for orphan drug designation for VGL101 for the treatment of CSF1R-related leukoencephalopathy, which
- GlobeNewswire
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month interim data from IGNITE trial in Q4 2023 from first 6 patients who have received 20 mg/kg of VGL101 - WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f
